User login
Key clinical point: Dupilumab rapidly reduced the skin abundance of Staphylococcus aureus in patients with moderate-to-severe atopic dermatitis (AD), and the reduction correlated with improvements in all AD severity measurements except itch.
Major finding: At day 3, the dupilumab vs placebo group showed a 7.5-fold reduction (P = .02) in the skin abundance of S. aureus. A significant positive correlation was observed between the reduction in abundance and SCORing Atopic Dermatitis score with dupilumab (repeated measure correlation coefficient 0.39; P < .001), which was similar for other AD severity measurements except pruritus Numeric Rating Scale score.
Study details: Findings are from the multicenter, double-blind ADRN09 trial including 71 adult patients with moderate-to-severe AD who were randomly assigned to receive dupilumab (n = 45) or placebo (n = 26).
Disclosures: This study was supported by the US National Institute of Allergy and Infectious Diseases and the National Center for Advancing Translational Sciences, Colorado. Some authors declared serving as consultants or investigators for and receiving research grants from various organizations.
Source: Simpson EL et al. Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatment. J Allergy Clin Immunol. 2023 (Jun 12). Doi: 10.1016/j.jaci.2023.05.026
Key clinical point: Dupilumab rapidly reduced the skin abundance of Staphylococcus aureus in patients with moderate-to-severe atopic dermatitis (AD), and the reduction correlated with improvements in all AD severity measurements except itch.
Major finding: At day 3, the dupilumab vs placebo group showed a 7.5-fold reduction (P = .02) in the skin abundance of S. aureus. A significant positive correlation was observed between the reduction in abundance and SCORing Atopic Dermatitis score with dupilumab (repeated measure correlation coefficient 0.39; P < .001), which was similar for other AD severity measurements except pruritus Numeric Rating Scale score.
Study details: Findings are from the multicenter, double-blind ADRN09 trial including 71 adult patients with moderate-to-severe AD who were randomly assigned to receive dupilumab (n = 45) or placebo (n = 26).
Disclosures: This study was supported by the US National Institute of Allergy and Infectious Diseases and the National Center for Advancing Translational Sciences, Colorado. Some authors declared serving as consultants or investigators for and receiving research grants from various organizations.
Source: Simpson EL et al. Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatment. J Allergy Clin Immunol. 2023 (Jun 12). Doi: 10.1016/j.jaci.2023.05.026
Key clinical point: Dupilumab rapidly reduced the skin abundance of Staphylococcus aureus in patients with moderate-to-severe atopic dermatitis (AD), and the reduction correlated with improvements in all AD severity measurements except itch.
Major finding: At day 3, the dupilumab vs placebo group showed a 7.5-fold reduction (P = .02) in the skin abundance of S. aureus. A significant positive correlation was observed between the reduction in abundance and SCORing Atopic Dermatitis score with dupilumab (repeated measure correlation coefficient 0.39; P < .001), which was similar for other AD severity measurements except pruritus Numeric Rating Scale score.
Study details: Findings are from the multicenter, double-blind ADRN09 trial including 71 adult patients with moderate-to-severe AD who were randomly assigned to receive dupilumab (n = 45) or placebo (n = 26).
Disclosures: This study was supported by the US National Institute of Allergy and Infectious Diseases and the National Center for Advancing Translational Sciences, Colorado. Some authors declared serving as consultants or investigators for and receiving research grants from various organizations.
Source: Simpson EL et al. Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatment. J Allergy Clin Immunol. 2023 (Jun 12). Doi: 10.1016/j.jaci.2023.05.026